Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms ARD-1630 |
Target |
Action degraders |
Mechanism AR degraders(Androgen Receptor degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H48ClN7O5 |
InChIKeyAJLHRCDOQDFNEX-UHFFFAOYSA-N |
CAS Registry2632304-07-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | United States | Oncopia Therapeutics, Inc.Startup | 08 Sep 2023 |
Prostatic Cancer | Preclinical | United States | 08 Sep 2023 |